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ABSTRACT
Susceptibility of patients to antibiotic-associated C. difficile disease is intimately associated with
specific changes to gut microbiome composition. In particular, loss of microbes that modify bile
salt acids (BSA) play a central role; primary bile acids stimulate spore germination whilst secondary
bile acids limit C. difficile vegetative growth. To determine the relative contribution of bile salt (BS)
metabolism on C. difficile disease severity, we treated mice with three combinations of antibiotics
prior to infection. Mice given clindamycin alone became colonized but displayed no tissue
pathology while severe disease, exemplified by weight loss and inflammatory tissue damage
occurred in animals given a combination of five antibiotics and clindamycin. Animals given only
the five antibiotic cocktails showed only transient colonization and no disease. C. difficile coloniza-
tion was associated with a reduction in bacterial diversity, an inability to amplify bile salt
hydrolase (BSH) sequences from fecal DNA and a relative increase in primary bile acids (pBA) in
cecal lavages from infected mice. Further, the link between BSA modification and the microbiome
was confirmed by the isolation of strains of Lactobacillus murinus that modified primary bile acids
in vitro, thus preventing C. difficile germination. Interestingly, BSH activity did not correlate with
disease severity which appeared linked to alternations in mucin, which may indirectly lead to
increased exposure of the epithelial surface to inflammatory signals. These data confirm the role
of microbial metabolic activity in protection of the gut and highlights the need for greater
understanding the function of bacterial communities in disease prevention.
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Introduction
Clostridiodes difficile is a disease of the gutmicrobiome
with onset associated with the use of antibiotics1 that
reduce bacterial diversity within the colon. It is the
leading cause of antibiotic-associated diarrhea (AAD)
and the main cause of pseudomembranous colitis
(PMC).2 Further, a significant number of patients
suffer relapsing disease3–5 following cessation of anti-
biotics (metronidazole and vancomycin) used in treat-
ment. Such episodes reflect persistent disruption of
the microbiota, creating an environment in which the
pathogen can flourish.6,7 Consequently, restoration of
microbiota diversity has become the focus for new
treatments including fecal microbiota transplantation
(FMT),8,9 defined bacterial therapies10–12 and more
recently sterile fecal filtrate transfer (FFT).13
Although these approaches frequently restore micro-
bial diversity within the niche and eliminate disease,
the long-term consequences of using undefined
microbial therapies on long-term health, is not yet
clear. This is relevant given the increasing burden of
evidence that gut microbes play a role in diseases
including diabetes, obesity and mental illness.14
These links have driven researchers to consider
which organisms can and should be included in
these preparations. Several groups have shown that
specified cocktails of bacterial speciesmaybe sufficient
to limit disease, at least in mice11,15 and whilst knowl-
edge of the identity of key players is increasing,11 for
such therapies to be successful and safe, it is important
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that we improve our understanding of the functional
contribution offered by each organism.
In the context of C. difficile germination, one role
performed by bacterial members of the gut micro-
biome is to modify bile acids (BAs). Primary bile
salts produced in the liver are released in the small
bowel and assist in the uptake of lipids and lipid-
soluble vitamins from the diet. The breakdown of
BAs is complex and involves several enzymes16
expressed by gut bacteria, the two most important in
the context of C. difficile, being bile salt hydrolases
(BSH) and the 7α-dehydroxylation (7αDH)
enzymes.17,18 Modification is relevant as primary bile
acid (pBA) taurocholic acid (TCA) induce spore ger-
mination whereasmodified secondary bile acid (sBA),
deoxycholic acid (DCA), are poor germinates and
inhibit vegetative cell outgrowth.19–21 BSH are
expressed by several members of the microbiota and
are important for the removal of the amino acid side-
chains, which allow other enzymes including the 7α-
dehydroxylases to function (Supplementary Figure 1).
This secondary process is more specialized and
restricted to a few species including Clostridium scin-
dens, Clostridium hylemonae, Clostridium sordellii,
Clostridium hiranonis and various unclassified
Eubacteria.22,23
Multiple antibiotics have been associated with
changes in BA metabolism including
streptomycin,24 cefoperazone,25,26 clindamycin26,27,
and vancomycin.26,28 The impact of disruption of
BAmetabolism andC. difficile disease has previously
been demonstrated using Cl. scindens, which modi-
fies cholic acid to produce DCA through the expres-
sion of a 7α-dehydroxylase. Treatment of C. difficile
infected mice with this strain-reduced mortality but
treatment was only fully protective whenCl. scindens
was combined with three other bacteria.11 This result
suggests that other metabolic functions may be
important in germination, colonization resistance,
and disease severity.
Until recently, one factor limiting progress was
the availability of an animal model that was tractable
toC. difficile infection and inwhich knowledge of the
microbiome was significant. Although the Golden
Syrian Hamster is recognized as the standard
model for the study of acute toxin-mediated
C. difficile disease, the rapid and fatal nature of
infection limits the study of changes to gut micro-
biome composition. However, two mouse models,
described in recent years have revealed that pre-
treatment with different combinations of antibiotics
prior to infection, can influence disease outcome.
For example, treatment with clindamycin alone can
render mice susceptible to transient colonization
with high numbers of C. difficile, which are then
suppressed by gut microbiome reestablishment.15
Interestingly, these animals remain asymptomatic
but persistently infected with low (almost undetect-
able) numbers of bacteria, which proliferate if micro-
biota diversity is modified by further antibiotic
treatment. In contrast, Chen et al., (2008)29 showed
that treatment with a cocktail of five antibiotics
(colistin, metronidazole, vancomycin kanamycin,
and gentamicin; the ABC cocktail) prior to clinda-
mycin (ABC+clindamycin) resulted in acute
disease.29 Animals lose weight, develop loose feces
and show significant gut pathology 2–3 days post-
infection. Differences, especially the degree of
epithelial damage and tissue disruption are signifi-
cant and probably reflect the virulence of C. difficile
strains and the diversity of gut microbiome of the
individual mouse.
To determine whether disease outcome reflected
changes in the composition and metabolic func-
tional activity of the gut microbiome, we com-
pared animals pre-treated with different
antibiotic regimens prior to infection. Using 16S
rRNA gene analysis (metataxonomics), amplifica-
tion of sequences encoding the BSH enzymes and
direct measurement of the abundance of bile salts,
we hoped to determine if the extent of bile salt
modification influenced disease severity.
Results
The impact of different antibiotic regimens on disease
severity was determined by treating animals as
described (Figure 1(a)). These animals were subse-
quently orally challenged with 1 × 105 C. difficile
B-I7 spores and animals monitored for changes in
behavior, appearance, and weight loss; animals show-
ing a drop in weight of greater than 15% were culled.
Colonization was determined by the recovery and
quantification of C. difficile from fresh fecal material.
Using these critertium, untreated, but infected animals
showednoweight loss and failed to become colonized.
Treatment with the ABC cocktail alone resulted in
transient colonization with significantly lower
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numbers of both spores and vegetative cells of
C. difficile detected in the feces compared to clinda-
mycin treatment (p = .0107) or ABC plus clindamycin
treatment (p = .0074) at 3DPI (days post-infection)
(Figure 1(b)). High bacterial loads (spores and vege-
tative cells) were recorded for animals given clinda-
mycin, either alone or in combination with ABC, in
both the feces (3DPI) and from cecal and colonic
tissue at the time of cull (4DPI) (Supplementary
Figure S2). Significant weight loss was noted between
infected animals pretreated with ABC+clindamycin
and untreated animals (p < .05) but not animals
treated with any other antibiotic combination
(Figure 1(c)). This result correlated with observations
of cecal and colonic tissue damage compared to those
given either ABC or clindamycin alone (Figure 1(d)).
Furthermore, at the time of cull (4DPI) the cecal index
(proportion of the body weight contributed by the
cecum), an indirect measurement of inflammation,
was significantly raised when animals were treated
with either combination of antibiotic. Interestingly,
combining antibiotic treatments further significantly
enhanced the cecal index compared to ABC or clin-
damycin alone treated mice (Figure 1(e)). As Toxin
a
d
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Figure 1. Antibiotic pre-treatment influences disease progression.
(a) Experimental outline indicating timing and antibiotic treatment regimens for each group. Red stars indicate time points of fecal collection
for microbiome sampling. Animals were culled D 4 post-infection. (b) Recovery of C. difficile in the feces of animals from different treatment
groups over time. Significance determined usingWelch’s T-test (* indicates p= .0107 and *** indicates p= .0074). (c) Meanweight inmice loss
following infection with C. difficile significance was determined using a one-way Anova with Tukey’s correction. There was no significant
difference between the untreated, ABC and clindamycin only groups at any time point. At 1 DPI the ABC + clindamycin treated mice lost
significantly more weight than the untreated and ABC groups (* = p < .05). At 2 DPI the ABC and clindamycin treated group lost significantly
more weight than all other groups (* = p < .05). At 3 DPI the ABC and clindamycin group had lost significantly more weight than the ABC
treated group (* = p < .05). (d) Representative hematoxylin and eosin (H + E) stained colonic tissue sections from infected animals pre-treated
with different antibiotics, taken 4 DPI (magnification x 200) (e) Cecal index (the proportion of body weight made up by the cecum)
measurements calculated from material recovered 4 days post-infection. Each data point represents the measurement taken from an
individual animal. Significant differences were calculated using a one-way Anova with Tukey’s correction (* p = < 0.01; ** p = < 0.003; ***
indicates p< .0003). (f) Toxin B activity within filtered cecal lavagematerial recovered 4 DPI. Each data point represents themeasurement from
an individual animal. These data are presented as the reciprocal of the first dilution in which cell rounding was not observed. In figures B, C, E,
and F data from animals treatedwith ABC alone are represented in green (n = 5); clindamycin alone, blue (n = 10); ABC+ clindamycin, red (n =
10) and no treatment, black (n = 5). Error bars, when included represent the standard error of the mean (SEM) for each group.
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AandToxin B produced by the bacteria are associated
with disease, functional activity of filtered cecal and
colonic contents from infected mice were tested.
Surprisingly, differences in toxin activity between
these groups did not correlate with pathology
(Representative Toxin B data is shown in Figure 1(f);
Toxin B activity in colon samples; Toxin A data not
shown). From this data, we determined that disease
severity was influenced by a non-toxin related mod-
ification to the niche.
Impact of antibiotic treatment on gut
microbiome community structure and
function
To determine if severity could be linked to changes
in microbial gut composition, a metataxonomic ana-
lysis was performed on DNA extracted from fecal
samples collected during the experiment (denoted by
red stars in Figure 1(a)). Interestingly, fecal material
from animals treated with ABC+clindamycin
appeared associated with visually greater amounts
of mucus observed during fecal collection. Further,
a substantial mucus layer was observed following the
centrifugation of this material.
Using three independent, but complementary
bioinformatic methods, the alpha and beta diversity
of the samples were assessed. This revealed that mice
treated with clindamycin or the ABC+clindamycin
cocktail showed the greatest microbial changes in the
gut microbiome (Figure 2(a)). These changes were
less apparent 3DPI, reflecting a recovery of the com-
position of the gut microbiomes. A PCoA Cluster
analysis of these samples revealed congruence of
samples prior to antibiotic treatment suggesting
a similarity in the structure of the bacterial commu-
nities in the gut microbiomes within these animals
(Figure 2(b)). Post-antibiotic treatment (D0) cluster-
ing was distinct between animals treated with ABC
alone and those given clindamycin treatment or
ABC+clindamycin. We concluded that significant
changes in bacterial community diversity were
dependent on antibiotic treatment.
As changes to BA metabolism and C. difficile
infection have been described previously11 we indir-
ectly analyzed metabolic functions in the gut micro-
biome to determine if genes encoding these enzymes
could predict infection susceptibility. Using
Tax4fun,30 which bioinformatically infers the
metabolic capability of the community based on
predictions ofmicrobiomemembers frommetataxo-
nomic analysis, the abundance of sequences encod-
ing the 7α-dehydroxylation enzymes, involved in
secondary metabolism of BA, were studied.
Apparent absence of these sequences may reflect
the relatively low percentage of organisms expressing
this enzyme. In contrast, work focusing on BSH, the
gateway enzyme for the pathway, showed BSH
sequences were reduced in mice treated with clinda-
mycin, or ABC+clindamycin (Figure 3(a), timepoint
D0, post-clindamycin treatment). In contrast,
a reduction at this timepoint was not observed in
animals given the ABC cocktail alone. To confirm
this observation, degenerate PCR primers that target
BSH genes were used to amplify these sequences
from fecal DNA samples. Bands of approximately
850 bp (subsequently sequenced and confirmed as
BSH) were amplified from samples taken prior to
treatment with clindamycin, from animals not
receiving antibiotics or those given the ABC cocktail
alone (Figure 3(b)) but not from those post-
clindamycin treatment. A second, alternative set of
degenerate BSH primers confirmed this observation
(data not shown). Thus, we concluded that clinda-
mycin treatment was sufficient to eliminate mem-
bers of the microbiota that influenced BA
modification through BSH activity. Time of flight
(TOF) Mass spectrometry analysis of BAs extracted
from the cecum of mice confirmed the relative abun-
dance of TCA and DCA in samples from infected
animals (Figure 3(c)). Comparison of single fecal
ions from cecal extracts revealed that treatment
with clindamycin was sufficient to modify the rela-
tive abundencies of BA (summary of bile salts ana-
lyzed is provided in supplementary Figure 3). In
particular, high levels of TCA were linked with clin-
damycin treatment (Figure 3(c-a, c-b); either alone
or in combination with ABC). In contrast, no differ-
ences in BA abundance were observed between the
clindamycin and the ABC+clindamycin treated
groups (Figure 3(c-c)).
Role of bile salt modification on C. difficile
spore germination and vegetative growth
To confirm the impact of different BAs on BI-7
spore germination, spores were inoculated into
growth medium containing 0.1% TCA, CA, or
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DCA, respectively (Figure 4(a)). As expected,
spores exposed to TCA germinated rapidly reach-
ing the stationary phase by 12 h, confirming TCA
induces germination. In contrast, equivalent
numbers of spores in BHI or BHI+CA, showed
a delay in germination and outgrowth (+12h),
indicating that CA is a less effective germinant.
No growth was observed in the culture which
included DCA, confirming that DCA inhibits
the vegetative outgrowth of C. difficile.
To directly confirm the link between TCA mod-
ification and the microbiome, several bacterial spe-
cies were cultured from fecal material. To identify
those strains capable of TCA modification, isolates
were grown in medium containing 0.1% TCA.
Spent media was then filtered to remove bacteria
and the resultant filtrate inoculated with C. difficile
spores. Whilst several isolates were unable to mod-
ify TCA and thus prevent C. difficile germination,
two strains of Lactobacillus murinus were isolated
with contrasting capacity to limit (S15) or allow
TCA induced spore germination (S12) (Figure 4
(b)) were identified. To determine if spore germi-
nation was related to BSH activity, the genomes of
both strains were sequenced and BSH-like
sequences annotated. This analysis confirmed
that BSH was encoded by both strains, however,
in S12, 39 nucleotides were missing from the start
Figure 2. Analysis of alpha and beta diversity from different antibiotic treatment groups.
Microbiome diversity was analyzed through amplification of the V4 region from 16S using DNA recovered from fecal samples from
individual mice. (a) The alpha diversity represented in each group was determined using three independent methods and data
represents changes observed over time in each treatment group. Box and whisker plot showing the minimum, maximum and mean
values for each treatment group for D − 5, D − 3, D − 2, D 0, and, D 3 are shown in pink, blue, brown, pale green and dark green,
respectively. For the untreated and clindamycin alone groups, samples were not tested at D − 3, D − 2 and for the untreated group
at D 0. (b). Changes in diversity over time in PcoA plots using Weighted Unifrac of beta diversity. Data represents diversity in fecal
samples taken from animals prior to antibiotic treatment (D − 5), post-antibiotic treatment but prior to infection D 0 and 3 days
post-infection (D 3). Dots represent animals that were untreated (pink), given clindamycin alone (blue), ABC + clindamycin (orange)
or ABC alone (green).
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of the annotated BSH gene, including a key
cysteine residue, essential for BSH activity16 and
the methionine start codon (Figure 4(c)). This
truncation was verified using primers designed to
amplify the truncated (939 bp) or full-length BSH
gene (978 bp), respectively (Figure 4(d)). This
observation highlights for the first time that the
functional activity of BSH may vary between iso-
lates of the same strain recovered from the micro-
biome. This is relevant given the search for defined
combinations of bacteria that have efficacy for
C. difficile treatment. In particular, it highlights
the need for careful characterization of strains
especially when assigning generic activities to par-
ticular strains of bacteria.
Impact of changes in the diversity of the
microbiome and disease severity
Whilst this evidence supports and extends knowledge
of BAmetabolism and colonization resistance, it failed
to establish why animals treated with ABC+clindamy-
cin develop acute disease. To explore this discrepancy,
differences in the bacterial species were compared
between animals pre-treated with clindamycin and
those given clindamycin+ABC. This revealed
a significant reduction in species that are normally
associated with mucus colonization with
a concurrent increase in mucus degrading species
(Tables 1 and 2 and Supplementary Table 1). These
data suggested that disease severity may be linked to
changes to the mucus barrier leading to increased
a b
c
Figure 3. The impact of different antibiotic regimes on the amplification of DNA encoding BSH and abundance of primary and
secondary BA.
(a) Prediction of the presence of microbes expressing enzymes involved in bile metabolism based on Tax4fun analysis. Differences in
groups treated with different antibiotics were compared by evaluation of 16S data generated from fecal DNA taken prior to (D − 5;
pink) and post-antibiotic treatment (D 0; purple) Box and whisker blots show the minimum, maximum and mean values calculated
using individual data sets for each mouse (n = 5). Significance using a Kruskal–Wallis test revealed a negative correlation following
clindamycin treatment (p = 5.9 x 10−5) and a positive correlation following ABC treatment (p = .048). There was a decrease after
combined ABC + clindamycin treatment but this was not statistically significant. (b) Representative PCR amplifications of BSH from
fecal DNA samples. BSH sequences were amplified from DNA recovered from the feces of mice prior to (D-5, D-3, D-2, D0) or post-
infection (D3) for each treatment group. (c) Comparative analysis of BAs recovered from cecal lavages from infected animals treated
with different antibiotics. The relative abundance of TCA and DCA BA’s were determined by mass spectrometry on cecal lavages
prepared at 4 DPI. The p (corr)[1] p values show the differences in (i) untreated vs clindamycin alone (ii) untreated animals vs ABC +
clindamycin (iii) clindamycin alone vs ABC + clindamycin.
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epithelial exposure to bothC. difficile and its toxins. To
explore this hypothesis, cecal and colonic tissue from
infected mice were stained with Alcian blue, which
binds to acidic polysaccharides, including mucopoly-
saccharides. This showed mucus was concentrated in
the crypt regions of tissue in untreated and uninfected
animals (Figure 5(a)), which was largely unaffected by
infection (Figure 5(b)). In contrast, the crypt mucus
appeared reduced in infected animals treated with
ABC+clindamycin (Figure 5(d)) compared to those
given clindamycin alone (Figure 5(c)). These results
led us to conclude that modification to the bacterial
complexity of the gut microbiome affects mucus
integrity. The consequential increase in OTUs asso-
ciated with mucin degradation and loss of mucin
dwellers may reflect these changes.
Discussion
The availability of immunological tools and trans-
genic animals have made mice increasingly the
model of choice for the study of C. difficile disease.
The transition to the mouse from the hamster has
been achieved through the identification of anti-
biotic regimens that allow for the study of both
colonization and disease.15,29 In this study, we
a b
c d
Figure 4. Impact of BA’s on spore germination and outgrowth.
(a) Germination and growth of C. difficile spores when grown in BHI broth alone (black), BHI supplemented with 0.1% TCA (dark
blue), CA (light blue), and DCA (red). Rapid and significant growth was observed in media supplemented with TCA reaching
significantly higher ODs at 9 h (** p < .01) and 12 h (*** p < .0001) compared to all other growth conditions. In contrast, no
significant growth was observed in media supplemented with DCA, 24 h post-inoculation (*** p < .0001) when compared to all other
growth conditions. Error bars represent ± the SEM of 3 biological replicates. Statistical significance was determined using ANOVA
with Tukey’s posttest. (b) Relative percentage of C. difficile spores undergoing germination in the presence of filtered culture
supernatants from two strains of L. murinus strains (L. murinus) S12 encoding a truncated BSH, no fill; L. murinus S15 encoding a full-
length BSH, black fill and media alone (hashed) grown in BHI with 0.1% TCA for 24 h. Error bars represent ± the SEM of 3 biological
replicates. Statistical analysis was performed using an ANOVA with Tukey’s posttest. (c) Sequences of BSH genes from BSH – ve and
BSH +ve L murinus strains were aligned in Clustalw2 and confirm the absence of the first 13 amino acids from the sequence
including an important Cys residue highlighted in yellow. D. PCR amplification of full length and truncated BSH in the two strains of
L. murinus isolated during this study.
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sought to understand the basis of differences in
disease outcome when animals were challenged
with the epidemic 027 strain BI-7. Whilst animals
showed the same patterns of disease as reported
elsewhere (weight loss and tissue damage in the
ABC+clindamycin group and transient coloniza-
tion in animals treated with clindamycin alone),
no mouse mortality was observed. Their survival
contrasts with studies using VP10463, which is
a naturally high toxin producer. This difference
may reflect the amount of toxin produced in vivo
or the protective influence of the bacterial gut
microbiome communities in mice sourced from
different commercial providers.
The evidence that bile metabolism influences
C. difficile infection is now significant both in vitro31
and in vivo,26 although the extent to which second-
ary BA influence germination and outgrowth varies
between clinical isolates.32 Consequently, attention
has focused on the relative abundance of BSH and
7α-dehydroxylase genes within gut samples follow-
ing antibiotic treatment. This study reveals that
organisms encoding BSH genes were largely elimi-
nated by clindamycin treatment alone. This change
directly correlated with alternations to TCA and
DCA concentrations, with high level of TCA found
in the caecums of mice from which high numbers of
C. difficile were recovered. Further isolation of
L. murinis strains from animals pretreatment
allowed confirmation that BSH activity influenced
C. difficile germination at least in vitro. Sadly, the
capacity to determine if these strains could prevent
disease in vivo was hampered by their sensitivity to
clindamycin. However, the observation that clinda-
mycin treatment alone eliminated BSH activity is
significant given that, a decrease in 10 OTU’s that
encode 67.3% of the BSH genes in patients with
recurrent infection compared to controls, has been
described.18
Although BSH carry out the gateway reaction for
bile metabolism, 7α-dehydroxylation is also an
important part of the pathway that generates DCA.
As shown here, CA does not induce spore germina-
tion and conversion of TCA to CA by a BSH produ-
cing L. murinus can reduce spore germination
in vitro. The cleavage of the amino acid from the
BA by the action of BSH results in the release of
taurine, which can be reduced to H2S. H2S is an
essential substrate for 7α-dehydroxylase producing
bacteria, suggesting that these bacterial populations
act synergistically.33 In fact, recovery of BSH activity
has been linked to increased 7α-dehydroxylation
activity within the gut microbiome of rats following
clindamycin treatment.34 In addition, a significant
increase in Clostridial species, DCA and 7α-
dehydroxylation activity was observed in mice fed
CA.35,36 These studies strengthen the hypothesis that
restoration of bile metabolism through the introduc-
tion of BSH producing bacteria, or through feeding
of CA, is achievable. It is feasible that many of the
therapeutic bacterial mixtures already contain
strains expressing BSH activity.10,15 In fact, the suc-
cessful cocktail used to treat mice by Lawley et al.,
Table 1. Significantly increased OTU representation in samples
from mice treated with ABC+Clindamycin compared to clinda-
mycin alone at D0.
Significantly Increased OTUs Adjusted P value
OTU_780 Parabacteroides 1.77E-18
OTU_ 11 Parabacteroides goldsteinii 2.55E-18
OTU_ 3 Parabacteroides distasonis 2.51E-15
OTU_ 2 Bacteroides thetaiotaomicron 1.76E-14
OTU_ 784 Parabacteroides 9.94E-14
OTU_772 Parabacteroides 3.52E-13
OTU_34 Firmicutes 1.18E-10
OTU_812 Parabacteroides 2.92E-09
OTU_ 22 Erysipelotrichaceae bacterium Alo17 7.83E-09
OTU_850 Parabacteroides 2.63E-08
OTU_468 Bacteroides 2.92E-08
OTU_24 Bacteroides intestinalis 3.07E-08
OTU_7 Enterococcus 1.15E-07
OTU_5 Allobaculum 1.25E-07
OTU_10 Barnesiella 3.44E-07
OTU_122 Unclassified bacteria 2.04E-05
OTU_40 Porphyromonadaceae 2.04E-05
OTU_17 Burkholderiales 2.65E-05
OTU_733 Parabacteroides distasonis 3.91E-05
OTU_755 Parabacteroides 3.95E-05
OTU_750 Parabacteroides 5.14E-05
OTU_734 Parabacteroides 5.25E-05
OTU_756 Parabacteroides 8.68E-05
OTU_ 64 Betaproteobacteria 9.65E-05
Table 2. Significantly decreased OTU representation in samples
from mice treated with ABC+Clindamycin compared to clinda-
mycin alone at D0.
Significantly decreased OTUs Adjusted P value
OTU_15 Lactobacillus johnsonii 7.87E-32
OTU_ 36 Porphyromonadaceae 8.14E-12
OTU_223 Lactococcus 2.37E-11
OTU_21 Enterobacteriaceae 2.31E-10
OTU_45 Lactobacillus intestinali 2.92E-09
OTU_91 Mucispirillum schaedleri 2.92E-09
OTU_181 Enterorhabdus mucosicola 1.24E-05
OTU_53 Porphyromonadaceae 2.60E-05
OTU_47 Odoribacter 3.95E-05
OTU_88 Lachnospiraceae 5.0929e−05
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(2012) contained a BSH producer we have identified
in other unpublished work. Further, the bacter-
iotherapy, ‘rePOOPulate’, a mixture of 33 bacterial
isolates used to treat patients, contains several poten-
tial BSH producers as well as bacteria that may be
capable of 7α-dehydroxylation including several
Clostridia and Eubacterium. These observations
hint at least onemechanism by which these formula-
tions may work. In this study, attempts to investigate
the 7α-dehydroxylation enzyme were unsuccessful.
However, metataxonomic analysis of the microbiota
pre- and post-clindamycin treatment did reveal
a significant decrease in OTU_69, which is
a member of the Clostridium XIVa cluster known
Figure 5. Modifications to mucin in mice treated with different antibiotic combinations.
Formalin-fixed colonic tissue sections taken from mice 4DPI were stained with Alcian Blue to allow visualization of mucin. Figure 5
shows a typical image taken from (a). untreated and uninfected animals, (b) untreated and infected animals, (c) clindamycin treated
and infected animals and (d) ABC+clindamycin animals. (Magnification x 200).
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to carry out this function; the loss of which has been
linked to decreased colonization of C. difficile within
the mouse model.37
From these data, we conclude that the observed
disease severity, between these two different mouse
models, is not pathogen driven, as no difference in
the levels of colonization or toxin production were
observed between treatment groups. This contrasts
with reports that suggest that BA derivatives such as
methyl cholate have a direct impact on toxin
actvity.38 In our hands, increased tissue pathology
was a consequence of antibiotic-associated modifica-
tion of the microbiota, directly influencing the envir-
onmental context of the niche and survival and
growth of both beneficial and harmful organisms.
Whilst the use of clindamycin was associated with
a bloom of Enterobacteriaceae39,40 addition of the
ABC cocktail was linked to changes in mucin asso-
ciated organisms. In particular, an increase in
Bacteroides thetaiotaomicron a specialized mucin
degrader41 and the loss of three mucus dwelling
species, Mucispirillum schaedleri, Enterohabdus
mucosicola, and Lactobacillus intestinalis. Further,
evidence that mucus degradation plays a role in
disease severity has been provided by human intest-
inal organoids, which showed that C. diffficile was
associated with both reduction of MUC2 produc-
tion, which, along with increased mucin degrada-
tion, resulted in a thinner mucin layer.42 In vivo,
animals treated with metronidazole (one of the five
antibiotics included in the ABC cocktail) and
infected with Citrobacter rodentium showed
increased disease severity which was linked to
reduced mucin production.43 The implication of
disruption to mucus layer homeostasis is that the
epithelial surface will be highly exposed to
C. difficile, its toxins (TcdA, TcdB, and CDT) and
to components of the gut microflora associated with
inflammatory signaling. The increased disease asso-
ciated with the ABC+clindamycin probably reflects
a combination of all three factors.
Changes to the nutritional environment as
a consequence of dysbiosis, induced by antibiotic
treatment, has also been implicated in CDI severity.
In particular, loss ofmany primary fermenters, such as
Lachnospiridae and Lactobacillus (significantly
reduced in this study) generates a niche in which
alternative primary fermenters organisms such as
B. thetaiotaomicron to proliferate, producing
alternative endproducts of fermentation, such as suc-
cinate that can be utilised by C. difficile as a carbon
source.44,45 In addition, sialic acid released following
mucus degradation can also be utilized by C. difficile
for growth.46 Further, in mono-associated rat studies,
B. thetaiotaomicron has been shown to increase goblet
cell differentiation and expression ofmucus utilization
genes. In these studies, this change was ameliorated by
administering Faecalibacterium prausnitzii which
restored homeostasis to this system. The implication
from this work is that these organisms work synergis-
tically to regulate the goblet cell generation andmucin
glycosylation.47
In addition to alterations in the abundance of
mucus-associated bacteria, ABC+clindamycin treat-
ment affected the number of species that belong to
the Parabacteroides genus, including P. goldsteinii and
P. distasonis. This observation is relevant as mice with
increased numbers of Parabacteroides and Bacteroides
have a more diffuse mucus layer48 which may explain
the increased quantity of mucus observed in mouse
feces. Increased representation of Parabacteroides has
also been associated with mice that shed persistently
high numbers of spores15 and also with mice that
succumb to C. difficile infection.37 Similarly, increases
in Parabacteroides have been noted in humans
infected with C. difficile suggesting either a role for
these bacteria in infection6,49 or the creation of
a nutritional niche in which they can flourish.
These data are in agreement with several other
studies that have sought to understand the impact of
different antibiotics on colonization resistance to C.
difficile.11,26,50 Although different combinations of
antibiotics have been tested, the importance of multi-
ple assemblies of bacteria including
Porphyromonadaceae, Lachnospiraceae, Lactobacillus,
and Alistipes, in limiting C. difficile growth is clear.
Whilst organisms capable ofmodifying bile acids offer
one mechanism of control, maintaining competition
for nutrition and energy offer a second. The capacity
of C. difficile to directly exploit the restructured nutri-
tional landscape as a consequence of antibiotic treat-
ment has recently been explored in mice using
a genome-scale metabolic model with
a transcriptome-enabled metabolite scoring
algorithm.51 This work revealed that C. difficile fer-
ment amino acids preferentially, but are also capable
of using host-derived glycan components as sources of
energy. This ability to exploit the environmental
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changes helps explains why C. difficile is so effective at
exploiting the modified niche. Whilst changes in
response to antibiotics may vary from person to per-
son, increased knowledge of the functional contribu-
tion of different populations will become increasingly
important, especially when treating vulnerable
patients. Furthermore, these data offer microbial
genes as potential markers of disease susceptibility.
For example, BSH in this study serves as a good mar-
ker for healthy bile metabolism, additionally, relative
proportions ofmucus degrading enzymes offer a good
indicator of disease susceptibility. Future work will
help establish if the representation of these markers
could help predict vulnerability to C. difficile disease.
Materials and methods
Bacterial strains
C. difficile strains BI-7 (genotype 027/BI, Toxinotype
III; clindamycinR, thiamphenicolR, erythromycinS,
tetracyclineS, ciprofloxacinR, vancomycinS) used in
this study was a kind gift from Dale Gerding.
Animal models
All procedures were performed in strict accordance
with the Animals (Scientific Procedures) Act 1986
with specific approval granted by the Home Office,
UK (PPL60/4218). Food and water were provided ad
libitum and animals kept at a constant room tem-
perature of 20–22°C with a 12-h light/dark cycle.
Groups of five C57/bl6 mice aged 6–8 weeks sup-
plied by Charles River (Edinburgh) were used in
each treatment group. The antibiotic cocktail was
administered ad libitum in the drinking water as
previously described29 with clindamycin given at
(150 mg/Kg), by oral gavage 2 days after the cessa-
tion of the antibiotic cocktail. Animals were each
challenged with 105 spores of C. difficile BI-7 1 day
after clindamycin treatment. Mice were monitored
closely post-infection and weighed daily to deter-
mine the severity of the disease. Animals with
a weight loss greater than 15% were culled.
C. difficile shedding and organ colonization
Fresh fecal samples collected daily were weighed,
serially diluted in PBS and cultured on Braziers
cycloserine, cefatoxaine, egg yolk (CCEY) agar at
37°C for 48 h. 4 days post-infection animals were
culled and the cecum and colon harvested.
Enumeration of total counts and spore-specific
counts in lumen associated (LA) material and tis-
sue associated (TA) were performed as previously
described.52
DNA extraction from feces – samples for
microbiome analyses
Multiple fresh fecal samples from individual animals
were collected from animals prior to ABC treatment
(D-5), immediately post ABC treatment (D-3) but
post ABC prior to clindamycin treatment (D-1)
post-clindamycin treatment (D 0) and 3 days post-
infection 3DPI (D3). Fecal samples were immedi-
ately processed using the FastDNATM Spin kit for
soil as to the manufacturer’s instructions. DNA was
stored at −80°C until required.
Toxin detection
Toxin assays were carried out as described
previously52 on filtered luminal content was col-
lected from the cecum and colon of infected mice.
Monolayers of Vero cells (kidney epithelial cells)
and HT-29 cells were used to evaluate Toxin B and
Toxin A activity, respectively. Results are
expressed as the reciprocal of the final dilution of
supernatant that caused cell rounding.52
Histology staining
Tissue samples were harvested from the cecum and
colon at postmortem and were immediately fixed in
10% formalin. Embedded tissue sections were cut and
stained with hematoxylin and eosin53 or Alcian Blue.
Cecal index as an indirect measurement of
inflammation
Cecal index was calculated by determining the
percentage of body weight that was made up by
the cecum. The organ was washed and the content
removed before weighing. Increased cecal weight
is a potential indicator of organ thickening and
edema that has been linked to increased
inflammation.
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Amplification of V4 region of 16S rRNA gene
The V4 regions of the 16S rRNA gene were amplified
and sequenced using the Illumina Miseq platform.
For each sample triplicate 25 µl PCR reactions were
carried out containing 12.5 µl of Phusion high fide-
lity master mix, 0.87 µl of Universal forward primer,
0.87 µl of indexed reverse primer, 1.25 µl of DMSO,
6.5 µl of nuclease-free water and 3 µl of DNA (2 ng).
Primers contained a 12 bp unique identifying Golay
Tag to allow multiplexing of samples (supplemen-
tary Table 2). Cycling conditions were 95°C for 5
min followed by 25 cycles at 95°C for 20 s, 60°C for
15 s and 72°C for 40 s followed by a final 72°C
extension for 10 min. Replicates were pooled and
gel purified using a Qiagen gel purification kit as to
the manufacturer’s instructions. Library preparation
and sample sequencing were performed at the
Liverpool Center for Genomic Research.
Availability of supporting data
The sequencing data are available on the European
Nucleotide Archive under the study accession
number: PRJEB34878 (http://www.ebi.ac.uk/ena/
data/view/PRJEB34878).
Preparation of spores for germination assay
C. difficile strains were maintained as spore stocks
at −80°C. Spore preparation was carried out as
described previously.52
Germination assays
Assays were carried out in triplicate with a minimum
of three biological replicates for each sample. BHI was
used as a negative control, BHI with 0.1% TCA as
a positive control of maximal germination. BHI con-
taining 0.1% CA or DCA were also included to con-
firm their role in germination.
To determine if the two L. murinus strains were
able to modify BA’s directly, 30 µl of overnight
culture grown in BHI was used to seed 3 ml of
BHI containing 0.1% TCA. The culture was grown
anaerobically for 24 h and culture supernatants
sterilized using a 0.2 μm Ministart® syringe filter
(Sartorius) to remove bacteria from the media.
The pH of the filtered supernatant was adjusted
to 7 and the media anaerobically conditioned for 2
h before the addition of 1x104/ml pre-prepared
spores (whose number was determined by inocu-
lation onto BHI plates containing 0.1% TCA). The
spores were incubated within the conditioned
media for 2 h to allow triggering of germination.
The samples were heated at 65°C for 20 min to kill
any spores in which germination had been
initiated. The number of non-germinated spores
within the sample was then determined by plating
the heated samples onto BHI agar containing 0.1%
TCA. The relative percentage of germinating
spores was calculated by subtracting the remaining
spores from the initial spore count to provide an
indication of the number of germinated vegetative
cells in the population. The percentage of spores
germinating was then calculated using the follow-
ing equation
Percentage germination
¼ vegetative cells=initial inoculumð Þ x100
Amplification of BSH sequence
Consensus-degenerate hybrid oligonucleotide
(Codehop) primers were designed as described
previously.54 These primers amplify multiple BSH
genes from microbiome samples using a single set of
primers. Cycling conditions were 95°C for 2 min,
followed by 30 cycles at 60°C with amplification at
75°C.55
Sequencing and genome assembly of
lactobacillus strains
A single colony of each L. murinus was inoculated
into 20 ml of MRS broth and grown statically at
37°C for 24 h. DNA was extracted using
a DNAEasy Blood and Tissue kit (Qiagen) as per
the manufactures’ instructions. DNA was stored at
−80°C until required. Genome sequencing was
performed at Glasgow Polyomics facility (GPF).
Low-quality sequences were trimmed and assem-
bly was carried out using Spades assembly tool.56
Annotation was carried out using PROKKA.57
Tax4Fun analysis30 was used to find the metabolic
function of the bacterial community by blastingOTUs
against SILVA v115 database as all relevant pathways
(KEGGdatabase release 64.0) available. For this study,
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we recovered 6,297 KEGG orthologs (enzymes) using
fctProfiling = TRUE in Tax4Fun() function. Although
the Tax4Fun-based metabolic predictions are limited
by the taxa available in the reference database, it pro-
vides a statistic called fraction-of-taxonomic-units-
unexplained (FTU), which reflects the quantity of
sequences that are assigned to a taxonomic unit but
are not transferable to KEGG reference organisms.
The summary statistics of FTUs in this study: [Min:
0.004319; 1st Quartile:0.012234; Median: 0.020940;
Mean: 0.028830; 3rd Quartile: 0.031007; Max:
0.137971] revealed a very high ~91% mean coverage
of taxa, increasing our confidence in the recovered
metabolic pathways.
Lactobacillus BSH PCR
Specific primers were designed to amplify the
Lactobacillus murinus BSH using genomic
sequence data (Supplementary Table 2). Cycling
conditions were 95°C for 2 min, followed by 30
cycles at 50°C with amplification at 75°C
Bile acid analysis and data processing
To determine the relative concentrations of bile acids
including TCA, DCA, cholic acid, tauromuricholic
acids and muricholic acids in the cecum of mice,
Ultra Performance Liquid Chromatography-
Quadrupole Time of Flight-Mass Spectrometry
(UPLC-QToF-MS; UPLC Acquity, Waters Ltd.;
Q-ToF Premier MS, Waters MS Technologies) was
used. Cecal bile acid extracts (8 µl) were injected into
a 2.1 × 100 mm (1.7 μm) HSS T3 Acquity column
(Waters Corp.,Milford,MA) and eluted using a linear
gradient of 15% B to 95% B (A = water + 0.1% formic
acid; B = acetonitrile + 0.1% formic acid) from 0 to 9
min and keeping for 1 min at 95% B followed by a 2
min column re-equilibration at 15% B. The quality
control sample, formed by pooling a small portion
from each sample, was injected every seven samples to
check the instrumental stability. The MS data was
recorded in negative electrospray mode with a scan
range of 50–1000 m/z.58 The data was pre-processed
using XC-MS59 package in R and the processed data
was imported into SIMCA-P (Sartorius-stedium
Biotech, Sweden) for principal component analysis
and orthogonal projections to latent structures discri-
minant analysis.
Statistical analysis
Statistical analysis was carried out in Graph Pad
Prism and R version 8.1. The tests and parameters
used are detailed in the figure legends throughout.
Tests used included T-test with Welch correction,
ANOVA with Tukey’s post-test and Kruskal–
Wallis with Dunn’s multiple comparisons.
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